You are here: Industry Insights > Pfizer

News List

FDA approves Pfizer’s Braftovi plus cetuximab to treat BRAFV600E-mutant metastatic CRC pharmaceutical-business-review
April 14, 2020
Pfizer has secured approval from the US Food and Drug Administration (FDA) for its Braftovi (encorafenib) plus cetuximab (Erbitux) to treat BRAFV600E-mutant metastatic colorectal cancer (CRC) after prior therapy.
Pfizer Advances Battle Against COVID-19 on Multiple Fronts contractpharma
April 14, 2020
Pfizer has released an update on important advances in the battle against the global COVID-19 pandemic.
ICON Signs New Service Agreement With Pfizer contractpharma
April 14, 2020
ICON plc, a global provider of drug and device development and commercialization services to the pharmaceutical, biotechnology and medical device industries, has signed a three-year agreement with Pfizer.
ISPE Award Honors New Pfizer Facility contractpharma
April 14, 2020
Engineered and designed by CRB, Andover Clinical Manufacturing Facility focuses on integration and flexibility to speed patient therapies.
Pfizer finds COVID-19 drug candidate, plots summer testing fiercebiotech
April 13, 2020
Pfizer has found a leading experimental drug candidate against SARS-CoV-2 and is planning to test the drug in the coming months.
Pfizer identifies lead coronavirus drug candidate pharmaceutical-technology
April 13, 2020
Pfizer has announced progress in its research programme to develop antivirals and vaccine for the Covid-19 coronavirus infection.
Pharma programmes for employees to volunteer in fight against COVID-19 europeanpharmaceuticalreview
April 07, 2020
Lilly, Merck and Pfizer have announced how they will enable their employees to volunteer in programmes to combat COVID-19 while on base pay.
Pfizer wins EU approval for MabThera biosimilar pharmatimes
April 03, 2020
Pfizer has bagged European approval for Ruxience (rituximab), a monoclonal antibody (mAb) and biosimilar to MabThera (rituximab).
Mylan and Pfizer delay Upjohn merger amid coronavirus pandemic pharmaceutical-technology
March 30, 2020
Mylan’s merger with Pfizer’s off-patent branded drugs unit Upjohn is now expected to close in the second half of this year due to the coronavirus pandemic.
Pfizer’s abrocitinib hits endpoints in late-stage atopic dermatitis study pharmatimes
March 23, 2020
Pfizer has revealed that its investigational Janus kinase 1 (JAK1) inhibitor, abrocitinib, has met its co-primary efficacy endpoints in a Phase III moderate to severe atopic dermatitis trial.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page